The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
Open accessAbstract
BACKGROUND: Microalbuminuria is an early predictor of diabetic nephropathy and premature cardiovascular disease. We investigated whether treatment with an angiotensin-receptor blocker (ARB) would delay or prevent the occurrence of microalbuminuria in patients with type 2 diabetes and normoalbuminuria. METHODS: In a randomized, double-blind, multicenter, controlled trial, we assigned 4447 patients with type 2 diabetes to receive olmesartan (at a dose of 40 mg once daily) or placebo for a median of 3.2 years. Additional antihypertensive drugs (except angiotensin-converting-enzyme inhibitors or ARBs) were used as needed to lower blood pressure to less than 130/80 mm Hg. The primary outcome was the time to the first onset of microalbuminuria. The times to the onset of renal and cardiovascular events were analyzed as secondary end points. RESULTS: The target blood pressure (<130/80 mm Hg) was achieved in nearly 80% of the patients taking olmesartan and 71% taking placebo; blood pressure measured in the clinic was lower by 3.1/1.9 mm Hg in the olmesartan group than in the placebo group. Microalbuminuria developed in 8.2% of the patients in the olmesartan group (178 of 2160 patients who could be evaluated) and 9.8% in the placebo group (210 of 2139); the time to the onset of microalbuminuria was increased by 23% with olmesartan (hazard ratio for onset of microalbuminuria, 0.77; 95% confidence interval, 0.63 to 0.94; P=0.01). The serum creatinine level doubled in 1% of the patients in each group. Slightly fewer patients in the olmesartan group than in the placebo group had nonfatal cardiovascular events--81 of 2232 patients (3.6%) as compared with 91 of 2215 patients (4.1%) (P=0.37)--but a greater number had fatal cardiovascular events--15 patients (0.7%) as compared with 3 patients (0.1%) (P=0.01), a difference that was attributable in part to a higher rate of death from cardiovascular causes in the olmesartan group than in the placebo group among patients with preexisting coronary heart disease (11 of 564 patients [2.0%] vs. 1 of 540 [0.2%], P=0.02). CONCLUSIONS: Olmesartan was associated with a delayed onset of microalbuminuria, even though blood-pressure control in both groups was excellent according to current standards. The higher rate of fatal cardiovascular events with olmesartan among patients with preexisting coronary heart disease is of concern. (Funded by Daiichi Sankyo; ClinicalTrials.gov number, NCT00185159.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a trial of people with type 2 diabetes and normal urinary albumin excretion, an ARB reduced or suppressed the development of albuminuria but increased the rate of cardiovascular events (86).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“but cardiovascular events were increased. 59”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Available data suggest that ACEi and ARB treatments are not bene fi cial for patients with neither albuminuria nor elevated blood pressure.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In T2D with neither albuminuria nor elevated blood pressure (normal or well-treated), moderately increased albuminuria was observed less frequently with an ARB”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a trial of people with type 2 diabetes and normal urinary albumin excretion, an ARB reduced or suppressed the development of albuminuria but increased the rate of cardiovascular events (94).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [94]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Self-citation2007 Guidelines for the Management of Arterial Hypertension
Mancia, G., Backer, G. D., Dominiczak, A. F., Cífková, R., Fagard, R. H., Germanò, G., Grassi, G. M., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,870
Self-citationMancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Self-citationTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
MICROALBUMINURIA AS A PREDICTOR OF CLINICAL NEPHROPATHY IN INSULIN-DEPENDENT DIABETES MELLITUS
Viberti, G. C., Jarrett, R. J., Mahmud, U., Hill, R. D., Argyropoulos, A. N., & KEEN, H. (1982) · The Lancet · doi:10.1016/s0140-6736(82)92450-3 · Cited by 1,662
Self-citationMancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M. J., Cifkova, R., Clément, D., Coca, A., Dominiczak, A., et al. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e328333146d · Cited by 1,643
Self-citationLindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Preserving renal function in adults with hypertension and diabetes: A consensus approach
Bakris, G. L., Williams, M. E., Dworkin, L. D., Elliott, W. J., Epstein, M., Toto, R. D., Tuttle, K. R., Douglas, J. G., Hsueh, W. A., & Sowers, J. R. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.16225 · Cited by 1,396
Relation Between Kidney Function, Proteinuria, and Adverse Outcomes
Hemmelgarn, B. R. (2010) · JAMA · doi:10.1001/jama.2010.39 · Cited by 1,042
Preventing Microalbuminuria in Type 2 Diabetes
Ruggenenti, P. L., Fassi, A., Parvanova, A. I., Bruno, S., Iliev, I. P., Brusegan, V., Rubis, N., Gherardi, G., Arnoldi, F., Ganeva, M. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042167 · Cited by 1,012
Mancia, G., Laurent, S., Agabiti‐Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M. J., Cífková, R., Clement, D. L., Coca, A., Dominiczak, A. F., et al. (2009) · Blood Pressure · doi:10.3109/08037050903450468 · Cited by 896
Self-citationRenal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791
Messerli, F. H., Mancia, G., Conti, C. R., Hewkin, A. C., Kupfer, S., Champion, A., Kolloch, R. E., Bénétos, A., & Pepine, C. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-12-200606200-00005 · Cited by 777
United States Renal Data System
Ward, R. (2011) · Cited by 527
Combining GFR and Albuminuria to Classify CKD Improves Prediction of ESRD
Hallan, S. I., Ritz, E., Lydersen, S., Romundstad, S., Kvenild, K., & Orth, S. R. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008070730 · Cited by 441
Self-citationMicroalbuminuria as an Early Marker for Cardiovascular Disease
de Zeeuw, D., Parving, H., & Henning, R. H. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050517 · Cited by 401
Sleight, P., Redón, J., Verdecchia, P., Mancia, G., Gao, P., Fagard, R. H., Schumacher, H., Weber, M. A., Böhm, M., Williams, B., et al. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832d7370 · Cited by 347
Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes
de Galan, B. E., Perkovic, V., Ninomiya, T., Pillai, A., Patel, A. A., Cass, A., Neal, B. C., Poulter, N. R., Harrap, S. B., Mogensen, C.-E., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008070667 · Cited by 273
Effect of Candesartan on Microalbuminuria and Albumin Excretion Rate in Diabetes
Bilous, R., Chaturvedi, N., Sjølie, A. K., Fuller, J., Klein, R., Orchard, T., Porta, M., & Parving, H.-H. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-1-200907070-00120 · Cited by 257
Effect of Telmisartan on Renal Outcomes
Mann, J. F. E., Schmieder, R. E., Dyal, L., McQueen, M. J., Schumacher, H., Pogue, J., Wang, X., Probstfield, J. L., Avezum, Á., Cardona-Munoz, E., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-1-200907070-00122 · Cited by 196
Systematic review on urine albumin testing for early detection of diabetic complications
Newman, D., Mattock, M., Dawnay, A., Kerry, S., McGuire, A., Yaqoob, M., Hitman, G., & Hawke, C. (2005) · Health Technology Assessment · doi:10.3310/hta9300 · Cited by 192
Urinary Albumin Excretion in Early and Long-Term Juvenile Diabetes
Mogensen, C. E. (1971) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365517109086899 · Cited by 165
Development of Renal Disease in People at High Cardiovascular Risk
Mann, J. F. E., Gerstein, H. C., Yi, Q., Lonn, E., Hoogwerf, B. J., Rashkow, A. M., & Yusuf, S. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000051594.21922.99 · Cited by 142
Haller, H. G., Viberti, G. C., Mimran, A., Remuzzi, G., Rabelink, T. J., Ritz, E., Rump, L. C., Ruilope, L. M., Katayama, S., Ito, S., et al. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000202820.56201.e6 · Cited by 106
Self-citationRuggenenti, P. L., Perna, A., Ganeva, M. G., Ene‐Iordache, B., & Remuzzi, G. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006060560 · Cited by 70
(2003) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.09.004 · Cited by 66
Flagged first, then by citations
Cited by
Sorted by citations
2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
Self-citationAhmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Self-citationMancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Self-citationStandards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Metadata
- Authors
- Haller, H., Ito, S., Izzo, J. L., Januszewicz, A., Katayama, S., Menne, J., Mimran, A., Rabelink, T. J., Ritz, E., Ruilope, L. M., Rump, L. C., & Viberti, G.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Tohoku University (JP)
- Institute of Cardiology (PL)
- Saitama Medical University (JP)
- Hôpital Lapeyronie (FR)
- Leiden University Medical Center (NL)
- Heidelberg University (DE)
- Hospital Universitario 12 De Octubre (ES)
- Heinrich Heine University Düsseldorf (DE)
- Guy's Hospital (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-03-10
- Volume
- 364
- Issue
- 10
- Pages
- 907-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2169506520
- Cited by
- 792
- References
- 30
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 19 · 2023: 26 · 2022: 39 · 2021: 36 · 2020: 39 · 2019: 34 · 2018: 58 · 2017: 51 · 2016: 59 · 2015: 67 · 2014: 66 · 2013: 74 · 2012: 115
- FWCI
- 80.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Amgen
- Pfizer
- Sanofi
- Bayer HealthCare
- Dainippon Sumitomo Pharma
- Astellas Pharma
- Shionogi
- Servier
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- olmesartan, microalbuminuria, type 2 diabetes, angiotensin receptor blockers, diabetic nephropathy, cardiovascular events, blood pressure control, renal protection, cardiovascular mortality, normoalbuminuria, serum creatinine doubling, antihypertensive therapy, renin-angiotensin system blockade, cardiovascular risk reduction
- MeSH terms
- Adolescent, Adult, Aged, Albuminuria, Blood Pressure, Cardiovascular Diseases, Coronary Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Imidazoles, Male, Middle Aged, Tetrazoles, Angiotensin II Type 1 Receptor Blockers, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
